Evidence for the Inhibition of Dengue Virus Binding in the Presence of Silver Nanoparticles
AIR FORCE INSTITUTE OF TECHNOLOGY WRIGHT-PATTERSON AFB OH SCHOOL OF ENGINEERING AND MANAGEMENT/DEPT OF ENGINEERING PHYSICS
Pagination or Media Count:
Dengue is an emerging hemorrhagic fever virus and widely considered the most important arbovirus in the world. Dengue virus DENV is a positive-sense RNA virus that exists in 4, potentially 5, antigenic serotypes. Currently, no vaccines or treatments are approved for DENV infections. Unsuccessful vaccine trials open the door for non-traditional treatments such as silver nanoparticles. Silver nanoparticles AgNP are known to inhibit viral replication of numerous viruses but have never before been tested for inhibition of dengue virus type 2 DENV2, ATCCregistered trademark VR-1584trademark. For the first time, this research presents up to a 96 reduction in DENV2 binding to Vero cells following pretreatment with AgNP 6-10nm, 25mugmL. These results suggest that similarly to other viruses, DENV2 can be inhibited at the first stage of the virus replication cycle, binding entry.